Carbonic anhydrase (6)
Molecular docking (6)
In silico study (5)
Sulfonamide (5)
DFT (4)
Cytotoxicity (3)
ICP-OES (3)
1 (2)
4-sulfamoylphenyl dithiocarbamate salt (2)
aldose reductase (2)
Aldose reductase inhibitors (2)
Benzenesulfonamide (2)
boron ore (2)
Boron waste (2)
in silico study (2)
molecular docking (2)
Oxadiazole (2)
Phthalocyanine (2)
processed boron ore (2)
Selective inhibitor (2)
Tetrazole (2)
(c) 2024 ACG Publications (1)
1, 4-Dihydropyridine (1)
1,2,3-triazole | Benzenesulfonamide | Carbonic anhydrase | In silico study | Isoindoline (1)
1,3,4-oxadiazol (1)
1,3,4-oxadiazol | Acetylcholinesterase | Carbonic anhydrase | In silico study | N-substituted sulfonyl amide (1)
1,3,4-oxadiazole (1)
1,3,4-oxadiazole | Rabbit Muscle Pyruvate Kinase | Tetrazole (1)
1,4-dihydropyridine (1)
1,4-Dihydropyridine (1)
1,4-Dihydropyridine | ADME | Dengue virus NS5 | DFT | Molecular docking | Oxadiazole | Tetrazole (1)
1,4-dihydropyridine | Cancer | Hantzsch reaction | Pyruvate kinase | Urea (1)
1,4-Dihydropyridine | DFT | Molecular Docking | Molecular Electronic Potential | Polyphenol Oxidase (1)
1,4-dihydropyridine | Drug score | Inhibition | Molecular docking | PON1 (1)
1,4-Dihydropyridine | Rabbit muscle pyruvate kinase | Sulfonamide (1)
2 (1)
2-(4-sulphonylamidebenzo)hydrazide-1-dithiocarbamate salt (1)
2-(4-sulphonylamidebenzo)hydrazide-1-dithiocarbamate salt | cloud point extraction (CPE) | Corn | ICP-OES | trace element (1)
3-triazole (1)
4-dihydropyridine (1)
4-Dihydropyridine (1)
4-sulfamoylphenyl dithiocarbamate salt | boron ore | Boron waste | cloud point extraction | ICP-OES | processed boron ore (1)
acetylcholinesterase (1)
Acetylcholinesterase (1)
acetylcholinesterase | beta-lactam | Carbonic anhydrase | in silico study | MCF-7 (1)
active pharmaceutical ingredient (1)
active pharmaceutical ingredient | density functional theory (DFT) | molecular docking | xanthine oxidase (XO) (1)
ADME (1)
ADME/Tox prediction (1)
ADME/Tox prediction | Aldose reductase inhibitors (ALR2 AKR1B1) | Diabetic complications / polyol pathway | Enzyme kinetics (competitive inhibition) | MM-GBSA binding energy | Molecular docking | Phthalimide–benzoic acid hybrids | Structure–activity relationship (SAR) (1)
Aldose reductase (1)
Aldose reductase | Cytotoxicity | Diabetic complication | In silico study | Inhibitor | Spiroindoline (1)
aldose reductase | in silico study | polyol pathway (1)
aldose reductase | isoindole-1,3-dione-based sulfonamides | tyrosinase | α-Glucosidase (1)
Aldose reductase inhibitors | Fluorenyl-phthalimide hybrids | Machine learning | Precision oncology | Rational drug design | Selective cytotoxicity | Targeted therapy (1)
Aldose reductase inhibitors | Lead optimization | Molecular docking and MM-GBSA | N-substituted phthalimides | Polyol pathway modulation | Protein-protein interaction | Structure-activity-energy relationship (1)
All rights reserved (1)
alpha-amylase (1)
alpha-Glucosidase (1)
alpha-glycosidase (1)
alpha-tetralone (1)
ALR2 inhibition (1)
ALR2 inhibition | cancer redox biology | Carbazole derivatives | Diabetic complications | Dual-action inhibitors | Indole hybrids | Molecular docking | Molecular dynamics | Oxidative stress | Phenothiazine scaffold | Quantum descriptors (1)
Anogenital warts | Awareness | Cervical cancer | Human papillomavirus | Public health strategies | Vaccination attitudes (1)
Anti-cancer (1)
Anti-cancer | Antimicrobial activity | Enzyme inhibitor | In silico | Phthalocyanine | Thioxothiazolidine (1)
Antimicrobial activity (1)
Benzenesulfonamide | Carbonic anhydrase | Cytotoxicity | In silico study | Selective inhibitor (1)
beta-lactam (1)
Bisoxadiazole (1)
Bisoxadiazole | Bovine carbonic anhydrase (bCA) | DFT | Molecular docking | Sulfonamide (1)
bovine carbonic anhydrase (1)
Bovine carbonic anhydrase (bCA) (1)
bovine carbonic anhydrase | molecular docking | Sulfonamide | thioalkyl substituted-1,3,4 oxadiazole (1)
Cancer (1)
cancer redox biology (1)
carbazole | Density Functional Theory (DFT) | EGFR | molecular docking | pkCSM | pyrido[2,3-d]pyrimidine | SwissADME | thiourea | urea | VEGFR-2 (1)
Carbazole derivatives (1)
carbazole derivatives | drug-likeness | EGFR | molecular docking | molecular dynamics | SwissADME | SwissTargetPrediction (1)
Carbonic anhydrase | Cytotoxicity | In silico study | Selective inhibitor | Sulfonamide (1)
carbonic anhydrase | enzyme inhibitor | thiourea (1)
Carbonic anhydrase | Molecular docking | Oxadiazole | Sulfonamide | Tirazole | α-amylase | α-glycosidase (1)
cloud point extraction (1)
cloud point extraction. (1)
Corn (1)
Cross-coupling reaction (1)
Cross-coupling reaction | Hydrogenation | Perlite | Reusable heterogeneous catalyst | Silica aerogel (1)
Cytotoxicity effects (1)
Cytotoxicity effects | Phthalocyanine | Quinazoline | Singlet oxygen | α-tetralone (1)
Dengue virus NS5 (1)
density functional theory (DFT) (1)
DFT | enzyme inhibitor | in silico | phthalocyanine | singlet oxygen (1)
Diabetic complication (1)
Diabetic complications (1)
Diabetic complications / polyol pathway (1)
Drug score (1)
Dual-action inhibitors (1)
enzyme inhibitor (1)
Enzyme inhibitor (1)
Enzyme kinetics (competitive inhibition) (1)
Fluorenyl-phthalimide hybrids (1)
Hantzsch reaction (1)
Hydrogenation (1)
In silico (1)
Indole hybrids (1)
Inhibition (1)
Inhibitor (1)
Isoindoline (1)
in silico (1)
isoindole-1,3-dione-based sulfonamides (1)
Lead optimization (1)
Machine learning (1)
MCF-7 (1)
MM-GBSA binding energy (1)
Molecular Docking (1)
Molecular docking and MM-GBSA (1)
Molecular dynamics (1)
Molecular Electronic Potential (1)
N -substituted phthalimides (1)
N-substituted sulfonyl amide (1)
Oxidative stress (1)
Perlite (1)
Phenothiazine scaffold (1)
Phthalimide-benzoic acid hybrids (1)
phthalocyanine (1)
polyol pathway (1)
Polyol pathway modulation (1)
Polyphenol Oxidase (1)
PON1 (1)
Precision oncology (1)
Protein-protein interaction (1)
Pyruvate kinase (1)
Quantum descriptors (1)
Quinazoline (1)
Rabbit muscle pyruvate kinase (1)
Rabbit Muscle Pyruvate Kinase (1)
Rational drug design (1)
Reusable heterogeneous catalyst (1)
Selective cytotoxicity (1)
Silica aerogel (1)
singlet oxygen (1)
Singlet oxygen (1)
Spiroindoline (1)
Structure-activity relationship (SAR) (1)
Structure-activity-energy relationship (1)
Targeted therapy (1)
thioalkyl substituted-1,3,4 oxadiazole (1)
Thioxothiazolidine (1)
Tirazole (1)
trace element (1)
tyrosinase (1)
Urea (1)
xanthine oxidase (XO) (1)
